Cargando…
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia
BACKGROUND: The question of which parameters may be informative on venetoclax outcome in chronic lymphocytic leukemia (CLL) is still unclear. Furthermore, the choice to treat with venetoclax can be challenging in patients with baseline characteristics or comorbidities that may potentially favor some...
Autores principales: | Frustaci, Anna Maria, Del Poeta, Giovanni, Visentin, Andrea, Sportoletti, Paolo, Fresa, Alberto, Vitale, Candida, Murru, Roberta, Chiarenza, Annalisa, Sanna, Alessandro, Mauro, Francesca Romana, Reda, Gianluigi, Gentile, Massimo, Varettoni, Marzia, Baratè, Claudia, Borella, Chiara, Greco, Antonino, Deodato, Marina, Zamprogna, Giulia, Laureana, Roberta, Cipiciani, Alessandra, Galitzia, Andrea, Curto Pelle, Angelo, Morelli, Francesca, Malvisi, Lucio, Coscia, Marta, Laurenti, Luca, Trentin, Livio, Montillo, Marco, Cairoli, Roberto, Tedeschi, Alessandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554118/ https://www.ncbi.nlm.nih.gov/pubmed/36246422 http://dx.doi.org/10.1177/20406207221127550 |
Ejemplares similares
-
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
por: Tedeschi, Alessandra, et al.
Publicado: (2021) -
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities
por: Frustaci, Anna Maria, et al.
Publicado: (2023) -
PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.
por: Innocenti, Idanna, et al.
Publicado: (2023) -
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
por: Fresa, Alberto, et al.
Publicado: (2022) -
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)